Our TEPI® Patch technology is based on a proprietary pressure-sensitive adhesive that incorporates the drug directly into its matrix for consistent and controlled delivery. Developed by Medherant, the adhesive has been well-tolerated in Phase I clinical trials, with no irritation or sensitisation. Its properties allow for the production of thin, flexible and attractive patches that stick securely to the skin yet are removed easily, leaving no residue.
Key benefits of our technology
High payload
Up to 50wt% achieved for drug and excipients
- Enables transdermal delivery of lower potency drugs
- Extended release (up to 7 days) formulations can be developed
- Smaller and more discrete patch can be produced
Better adhesion
Sticks even when wet
- More consistent dose delivery as entire patch remains in contact with the skin
- No cold-flow of adhesive around the edges of the patch
- Easy and painless to remove like a sticking plaster
Other Benefits
Flexibility to optimise delivery
- Efficient release of drug
- Less residual drug in the patch on removal
- Rates of flux can be customised to achieve desired product profile
- Solvent-free manufacturing process
Medherant’s TEPI Patch® technology provides a powerful platform for the development of a wide range of transdermal products, including drugs where patch delivery was previously not viable and patches for sustained delivery of drugs over a prolonged period.
The rate of drug release from the TEPI Patch can be tailored by adjusting the excipients in the formulation, allowing the pharmacokinetic profile to be matched to patient needs. Due to the adhesive’s high loading capacity, a broader range of excipients can be included and less adhesive is required to deliver the full dose.
